Health & Science · November 9, 2026
GLP-1 drugs, popular for weight loss, get FDA warning of rare vision-loss side effect
FreeGet stories like this compared, every morning at 7.
The Food and Drug Administration (FDA) has ordered manufacturers of GLP-1 medications—including popular brands like Ozempic, Wegovy, Zepbound, and Mounjaro—to update their safety labels with a warning regarding a rare eye condition. Known as nonarteritic anterior ischemic optic neuropathy (NAION), the condition is caused by reduced or blocked blood flow to the optic nerve and can lead to permanent, sudden vision loss. The FDA's decision followed a review of adverse event reports and a 2024 study that found diabetes patients on semaglutide were significantly more likely to develop the condition. Health officials and the FDA advise patients to seek immediate medical attention if they experience sudden, painless vision changes, as there is currently no proven treatment or cure for NAION.
Read the original coverage
- New York PostTabloid
GLP-1 drugs must have new warning label over incurable blindness condition, says FDA
Read at New York Post ↗ FDA tells GLP-1 makers to warn of potential vision loss side effect
Read at Washington Post ↗- CBS NewsMainstream
GLP-1 drugs, popular for weight loss, get FDA warning of rare vision-loss side effect
Read at CBS News ↗ - Associated PressWire
FDA adds rare vision-loss warning to popular GLP-1 drugs
Read at Associated Press ↗ - NBC NewsMainstream
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
Read at NBC News ↗
Reported by multiple outlets
- The FDA is requiring new safety warnings on GLP-1 drugs for diabetes and weight loss.
- The warning concerns a rare condition called nonarteritic anterior ischemic optic neuropathy (NAION).
- NAION can cause permanent vision loss or blindness and currently has no proven cure.
- The condition involves decreased blood flow to the optic nerve.
- A 2024 study linking semaglutide to an increased risk of NAION influenced the FDA's decision.
Reported by only some outlets
- NBC News, New York Post, and CBS News report the announcement occurred on Monday, Nov. 9.
- NBC News and CBS News specify the warning applies to all GLP-1 drugs, including injectable and pill-based versions.
- NBC News and New York Post note the 2024 study found diabetes patients on semaglutide were four times more likely to develop the condition.
- CBS News identifies Dr. Joseph Rizzo as a co-author of the 2024 paper who had been working with the FDA.
- The New York Post lists specific symptoms such as blurred vision, missing patches of sight, and distorted colors.
What the evidence actually shows
A 2024 medical study found that patients with diabetes taking semaglutide were approximately four times more likely to develop nonarteritic anterior ischemic optic neuropathy (NAION) compared to those not on the medication. The condition results from a sudden drop in blood flow to the optic nerve, causing vision loss that is often noticed upon waking and is currently irreversible.
FreeDaily Brief newsletter
Get the 5-minute Daily Brief, with the topics you pick.
The Daily Brief is free
About these outlets
CadNews does not determine absolute truth or endorse political viewpoints. It compares publicly available reporting, identifies shared facts, highlights framing differences, and flags uncertainty.